Oncology

For more than 30 years, there has been little treatment advancement for NMIBC patients. Fortunately, a new development in the treatment of NMIBC has been approved by the FDA and is now available.

The ACCC 50th Annual Meeting & Cancer Center Business Summit is taking place in Washington, DC from February 28 to March 1.

The sNDA was based on results from the KRYSTAL-1 study, evaluating the drug alone or in combination with other anti-cancer therapies in those with advanced solid tumors who have KRASG12C mutations.

The withdrawal comes after clinical trial results failed to demonstrate the safety and efficacy of melphalan flufenamide when combined with dexamethasone.

The recommendation comes after positive phase 3 trial results in adult patients with relapsed and refractory multiple myeloma.

A brief overview of 4 recent developments in the treatment of non-small cell lung cancer.

As of January 2024, Keytruda has been approved for 6 indications in NSCLC across the metastatic and earlier stages of the disease.

The model implemented at City of Hope Chicago has been shown to improve provider workloads and enrich pharmacists’ work.

Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.

Precision oncology represents an evolution in therapeutic practice.

Currently, ocifisertib is being evaluated in a phase 1b and 2 trial to confirm the safety and tolerability profiles in patients with acute myeloid leukemia.

Teclistamab was previously approved in October 2022 for the treatment of adult patients with relapsed or refractory multiple myeloma who received at least 4 prior therapies.

BAT1706 was clinically equivalent to the reference bevacizumab for efficacy, safety, pharmacokinetics, and immunogenicity.

Smoking 20 cigarettes per day significantly increased risk of death caused by certain types of melanomas.

These combination therapies have demonstrated longer PFS with a tolerable AE profile.

Datopotamab deruxtecan is an investigational TROP2 directed antibody drug conjugate that showed positive survival impact compared to chemotherapy.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

Researchers from Gilead remain confident for positive results as they continue the phase 3 EVOKE-03 study in 1L metastatic PD-L1-high NSCLC.

Certain patients may present asymptomatically, affecting treatment options.

Osimertinib was previously approved as a monotherapy, the first-in-line global standard of care, for non–small cell lung cancer indications.

The pharmacist’s role may vary across different practices and institutions.

This marks the first and only time that an individualized T cell therapy has been approved by the FDA for a solid tumor cancer.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

Tucatinib significantly improved median PFS in the overall population and those with brain metastases.

The complexity of the disease and number of treatment options can necessitate a personalized approach.

The investigators note that patients with newly diagnosed multiple melanoma who receive quadruplet treatment have unmet needs that must be further examined in future research.

Since the first FDA biosimilar approval of filgrastim-sndz (Zarxio) in 2015, a total of 44 biosimilars for 15 originator products have been approved and more than 20 are marketed.

The oral therapy is available through a REMS program.